Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

被引:347
|
作者
Wu, Jason H. Y. [1 ]
Foote, Celine [1 ,2 ]
Blomster, Juuso [1 ,3 ,4 ]
Toyama, Tadashi [1 ]
Perkovic, Vlado [1 ,5 ]
Sundstrom, Johan [1 ,6 ]
Neal, Bruce [1 ,7 ]
机构
[1] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2050, Australia
[2] Concord Repatriat Gen Hosp, Sydney, NSW, Australia
[3] Univ Turku, Turku, Finland
[4] Univ Gothenberg, Sahlgrenska Acad, Gothenburg, Sweden
[5] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[6] Uppsala Clin Res Ctr, Dept Med Sci, Uppsala, Sweden
[7] Univ London Imperial Coll Sci Technol & Med, London, England
来源
LANCET DIABETES & ENDOCRINOLOGY | 2016年 / 4卷 / 05期
基金
英国医学研究理事会;
关键词
INADEQUATE GLYCEMIC CONTROL; ADD-ON THERAPY; SELECTIVE SGLT2 INHIBITOR; DRUG-NAIVE PATIENTS; LONG-TERM EFFICACY; DOUBLE-BLIND; BLOOD-PRESSURE; BODY-WEIGHT; FOLLOW-UP; DAPAGLIFLOZIN MONOTHERAPY;
D O I
10.1016/S2213-8587(16)00052-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to increase LDL cholesterol and the incidence of urogenital infections. Protection against cardiovascular events has also been reported, as have possible increased risks of adverse outcomes such as ketoacidosis and bone fracture. We aimed to establish the effects of SGLT2 inhibitors on cardiovascular events, death, and safety outcomes in adults with type 2 diabetes, both overall and separately for individual drugs. Methods In this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Library, and websites of US, European, and Japanese regulatory authorities from Jan 1, 1950, to Sept 30, 2015, for data from prospective randomised controlled trials assessing the effects of SGLT2 treatment compared with controls. We excluded duplicate reports, trials of compound drugs, trials that lasted 7 days or fewer, trials that did not report on outcomes of interest, and articles that presented pooled trial data for which the individual trials could not be identified. We extracted data in duplicate using a standardised approach. The primary outcome was major adverse cardiovascular events. Secondary outcomes were cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, admission to hospital for unstable angina, heart failure, and all-cause mortality. We estimated summary relative risks with fixed-effects meta-analysis, with the I-2 statistic used to estimate heterogeneity of results beyond chance. Findings The analyses included data from six regulatory submissions (37 525 participants) and 57 published trials (33 385 participants), which provided data for seven different SGLT2 inhibitors. SGLT2 inhibitors protected against the risk of major adverse cardiovascular events (relative risk 0.84 [95% CI 0.75-0.95]; p=0.006), cardiovascular death (0.63 [0.51-0.77]; p<0.0001), heart failure (0.65 [0.50-0.85]; p=0.002), and death from any cause (0.71 [0.61-0.83]; p<0.0001). No clear effect was apparent for non-fatal myocardial infarction (0.88 [0.72-1.07]; p=0.18) or angina (0.95 [0.73-1.23]; p=0.70), but we noted an adverse effect for non-fatal stroke (1.30 [1.00-1.68]; p=0.049). We noted no clear evidence that the individual drugs had different effects on cardiovascular outcomes or death (all I I-2 < 43%). Safety analyses showed consistent increased risks of genital infections (regulatory submissions 4.75 [4.00-5.63]; scientific reports 2.88 [2.48-3.34]), but findings for some safety outcomes varied depending on whether anlayses were based on data extracted from regulatory submissions or trials reported in the scientific literature. Interpretation These data suggest net protection of SGLT2 inhibitors against cardiovascular outcomes and death. The efficacy results were driven by findings for empagliflozin (the only SGLT2 inhibitor for which data from a dedicated long-term cardiovascular safety trial have been reported), although results for the other drugs in the class were not clearly different. Adverse events were more difficult to quantify than was efficacy, with the effects of individual drugs in the class seeming to differ for some safety outcomes. Results from ongoing studies will be crucial to substantiate these findings across the drug class, but the available data provide a strong rationale to expect benefit from use of SGLT2 inhibitors in patients with type 2 diabetes at high risk of cardiovascular events.
引用
收藏
页码:411 / 419
页数:9
相关论文
共 50 条
  • [31] Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Wang, Jing
    Li, Xin
    Li, Yang
    Lei, Chen
    BMC ENDOCRINE DISORDERS, 2024, 24 (01)
  • [32] Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation
    Wang, Dong-Dong
    Mao, Yi-Zhen
    Yang, Yang
    Wang, Tian-Yun
    Zhu, Ping
    He, Su-Mei
    Chen, Xiao
    JOURNAL OF DIABETES RESEARCH, 2022, 2022
  • [33] Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Cardiovascular Outcomes: A Review of Literature
    Mani, Sweatha
    Balasubramanian, Abirami
    Veluswami, Keerthana
    Rao, Sudipta
    Aggarwal, Shailesh
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [34] Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis
    Hu, Xiaodong
    Yang, Yue
    Hu, Xiaona
    Jia, Xiaomeng
    Liu, Hongzhou
    Wei, Minjie
    Lyu, Zhaohui
    DIABETES OBESITY & METABOLISM, 2022, 24 (02): : 228 - 238
  • [35] Risk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials
    Rong, Xi
    Zhu, Yawen
    Wen, Bo
    Liu, Kai
    Li, Xinran
    Gou, Qiling
    Chen, Xiaoping
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [36] Sodium-Glucose Cotransporter 2 Inhibitors and their Renal benefits in type 2 diabetes. A Systematic Review
    Rehman, Saad Ur
    Rahman, Faiqa
    WORLD FAMILY MEDICINE, 2020, 18 (08): : 57 - 68
  • [37] Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis
    Ruanpeng, Darin
    Ungprasert, Patompong
    Sangtian, Jutarat
    Harindhanavudhi, Tasma
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33 (06)
  • [38] Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment
    Weir, Matthew R.
    POSTGRADUATE MEDICINE, 2019, : 367 - 375
  • [39] Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials
    Saad, Marwan
    Mahmoud, Ahmed N.
    Elgendy, Islam Y.
    Abuzaid, Ahmed
    Barakat, Amr F.
    Elgendy, Akram Y.
    Al-Ani, Mohammad
    Mentias, Amgad
    Nairooz, Ramez
    Bavry, Anthony A.
    Mukherjee, Debabrata
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 228 : 352 - 358
  • [40] The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Type 2 Diabetes Mellitus
    Taylor, Shawn Riser
    Harris, Kira B.
    PHARMACOTHERAPY, 2013, 33 (09): : 984 - 999